PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15191166-9 2004 CD4+ helper cells were almost nondetectable in transplanted rats that received CsA, but also only minimally elevated in transplanted rats that received vehicle. Cyclosporine 79-82 Cd4 molecule Rattus norvegicus 0-3 14550820-1 2003 BACKGROUND: The purpose of the study was to evaluate the effects of cyclosporine (CsA), FK 506 and mycophenolate mofetil (MMF) on graft-infiltrating leukocytes (CD4, CD8, CD11a, CD18) after cardiac transplantation in rats. Cyclosporine 68-80 Cd4 molecule Rattus norvegicus 161-164 11688669-12 2001 There was a statistically significant reduction in the number of CD4+, CD8+ as well as CD45+ cells in both the RAD- and the CSA-treated animals compared with the allogeneic control. Cyclosporine 124-127 Cd4 molecule Rattus norvegicus 65-68 14550820-7 2003 RESULTS: CsA and FK 506 reduced the presence graft-infiltrating leukocytes (CD4, CD8, CD11a, CD18) in the PVS of intra- and epicardial arteries when compared with control animals. Cyclosporine 9-12 Cd4 molecule Rattus norvegicus 76-79 8803575-10 1996 Significantly enhanced decreases in levels of CD 4+ lymphocytes were observed following treatment with CsA, LF, and, particularly, therapy with RIB 5/2 and a subtherapeutic dose of CsA. Cyclosporine 103-106 Cd4 molecule Rattus norvegicus 46-50 10482841-9 1999 Cyclosporin A had no significant effect on BHR and neutrophil accumulation but reduced the number of bronchoalveolar lavage eosinophils (P <.002), airway submucosal eosinophils, and CD4(+) and CD8(+) T cells (P <.02). Cyclosporine 0-13 Cd4 molecule Rattus norvegicus 185-188 11406149-5 2001 The expression of CD8alpha in mitogen-stimulated CD4(+) cells was blocked completely by calcineurin inhibitors (cyclosporine A and FK-506), and partially by rapamycin and SDZ-RAD. Cyclosporine 112-126 Cd4 molecule Rattus norvegicus 49-52 10362751-6 1999 Additionally, therapeutic CsA treatment decreased the number of IFN-gamma-producing CD4(+) naive and memory T cells in the spleen. Cyclosporine 26-29 Cd4 molecule Rattus norvegicus 84-87 9353152-6 1997 The results revealed that CsA blocks maturation of double-positive TCR(int) to double-positive TCR(high) thymocytes and preferentially inhibits the development of mature CD4 single-positive thymocytes. Cyclosporine 26-29 Cd4 molecule Rattus norvegicus 170-173 8958274-0 1996 The lesions of cyclosporine-induced autoimmune disease can be equally well elicited by CD4 or CD8 effector T cells. Cyclosporine 15-27 Cd4 molecule Rattus norvegicus 87-90 8803575-10 1996 Significantly enhanced decreases in levels of CD 4+ lymphocytes were observed following treatment with CsA, LF, and, particularly, therapy with RIB 5/2 and a subtherapeutic dose of CsA. Cyclosporine 181-184 Cd4 molecule Rattus norvegicus 46-50 8803575-12 1996 In contrast, the combination of RIB 5/2 and CsA (1.5 mg/kg) resulted in a reactive increase in levels of CD 8+ lymphocytes as well as an increased expression of RT 1b by the remaining CD 4+ lymphocytes. Cyclosporine 44-47 Cd4 molecule Rattus norvegicus 184-188 7499064-7 1995 Only the CD4+ cell population was increased on day 15 in AIA, and this increase was inhibited by CsA. Cyclosporine 97-100 Cd4 molecule Rattus norvegicus 9-12 7586742-8 1995 As a possible effector mechanism CD4+ T-cells in the acute-phase of CsA-AI may cause the observed activation of macrophages and keratinocytes. Cyclosporine 68-71 Cd4 molecule Rattus norvegicus 33-36 7826608-0 1994 Anti-CD4 monoclonal antibody treatment in combination with total lymphoid irradiation and cyclosporin A in hamster-to-rat cardiac transplantation. Cyclosporine 90-103 Cd4 molecule Rattus norvegicus 5-8 7692621-8 1993 The analysis of lymphocyte subsets proved the decrease of W3/25: OX8 ratio in both FK506- and cyclosporin-treated groups. Cyclosporine 94-105 Cd4 molecule Rattus norvegicus 58-63 8434390-2 1993 CD4+ cells from CsA-treated DA rats with long-surviving PVG heart allografts specifically suppress the capacity of naive CD4+ cells to restore allograft rejection in irradiated DA rats, but have normal donor-specific alloreactivity in MLC. Cyclosporine 16-19 Cd4 molecule Rattus norvegicus 0-3 8434390-2 1993 CD4+ cells from CsA-treated DA rats with long-surviving PVG heart allografts specifically suppress the capacity of naive CD4+ cells to restore allograft rejection in irradiated DA rats, but have normal donor-specific alloreactivity in MLC. Cyclosporine 16-19 Cd4 molecule Rattus norvegicus 121-124 8434390-3 1993 CD4+ suppressor cells from CsA-treated DA rats cultured for 3 days against either PVG or DA spleen cells lost the capacity to transfer suppression into irradiated DA rats grafted with PVG hearts and regained the ability to mediate rejection. Cyclosporine 27-30 Cd4 molecule Rattus norvegicus 0-3 8434390-5 1993 CD4+ cells from CsA-treated rats cultured against either third-party stimulator cells or syngeneic cells expressing anti-PVG idiotype in media supplemented with Con A supernatant failed to maintain suppressor cell function. Cyclosporine 16-19 Cd4 molecule Rattus norvegicus 0-3 8434390-6 1993 CD4+ cells from CsA-treated rats cultured in media supplemented with Con A supernatant alone also failed to maintain suppressor function. Cyclosporine 16-19 Cd4 molecule Rattus norvegicus 0-3 8434390-10 1993 These studies demonstrate that the CD4+ suppressor cell from CsA-treated rats with long-surviving grafts is short-lived; its survival is dependent upon contact with specific alloantigens and cytokines, one of which is IL-2. Cyclosporine 61-64 Cd4 molecule Rattus norvegicus 35-38 7915954-0 1993 Anti-CD4 monoclonal antibody treatment combined with total lymphoid irradiation and cyclosporin A in hamster-to-rat cardiac transplantation. Cyclosporine 84-97 Cd4 molecule Rattus norvegicus 5-8 2136906-4 1990 CD4+ cells from rats with long survival grafts specifically lack the capacity to restore PVG heart graft rejection, and can also inhibit the capacity of naive T cells to restore rejection, while in the first few weeks post-transplant, both CD4+ and CD8+ T cells from CSA-treated hosts have the capacity to effect PVG graft rejection. Cyclosporine 267-270 Cd4 molecule Rattus norvegicus 0-3 1652970-4 1991 Notably, CyA-treated syngeneic bone marrow chimeras (SBMC) had transiently increased numbers of peripheral CD4+ CD8+ T-cells, expressing a marker normally limited to thymocytes. Cyclosporine 9-12 Cd4 molecule Rattus norvegicus 107-110 2136906-5 1990 In this study, we demonstrated the CD4+ suppressor cells also had the capacity to inhibit restoration of rejection by CD4+ cells from CSA-treated DA rats recently transplanted with PVG hearts, and from rats sensitized to third party, but not from those specifically sensitized to PVG. Cyclosporine 134-137 Cd4 molecule Rattus norvegicus 35-38 2136906-5 1990 In this study, we demonstrated the CD4+ suppressor cells also had the capacity to inhibit restoration of rejection by CD4+ cells from CSA-treated DA rats recently transplanted with PVG hearts, and from rats sensitized to third party, but not from those specifically sensitized to PVG. Cyclosporine 134-137 Cd4 molecule Rattus norvegicus 118-121 2136906-7 1990 These results showed that the CD4+ suppressor cell was capable of overriding the capacity to effect rejection of the CD4+ cell and activated CD8+ cells that were present in the CSA-treated host shortly after transplantation. Cyclosporine 177-180 Cd4 molecule Rattus norvegicus 30-33 2136906-7 1990 These results showed that the CD4+ suppressor cell was capable of overriding the capacity to effect rejection of the CD4+ cell and activated CD8+ cells that were present in the CSA-treated host shortly after transplantation. Cyclosporine 177-180 Cd4 molecule Rattus norvegicus 117-120 2136906-13 1990 These studies demonstrated the CD4+ suppressive cell identified in rats with specific unresponsiveness induced by CSA therapy had many features of the suppressor inducer cell identified in in vitro studies of the alloimmune response. Cyclosporine 114-117 Cd4 molecule Rattus norvegicus 31-34 2516375-4 1989 During Cy-A administration CD4(+)-cell regeneration was almost completely suppressed, but within 3 weeks after withdrawal of the drug such cells reappeared in blood and reached pre-irradiation levels about 6 weeks later. Cyclosporine 7-11 Cd4 molecule Rattus norvegicus 27-30 2795127-5 1989 We found that the W3/25/MRCOX-8 ratio increased to 3.2 +/- 0.3 in the PAN rats but significantly decreased to 2.8 +/- 0.3 with CY treatment. Cyclosporine 127-129 Cd4 molecule Rattus norvegicus 18-23 28094770-6 2017 In contrast, treating activated rCD4s with the immunosuppressant cyclosporin, a calcineurin inhibitor, robustly inhibited HIV-1 reactivation. Cyclosporine 65-76 Cd4 molecule Rattus norvegicus 32-36 2888824-11 1987 The coadoptive transfer of cells resulted in the suppression of resistance afforded by the W3/25+ cells by OX8+ cells, which could be augmented in vitro by cyclosporin A. Cyclosporine 156-169 Cd4 molecule Rattus norvegicus 91-96 28473245-19 2017 Co-administration of Phela 15mg/kg/day orally for 21 days with CsA led to stoppage and reversal of the immunosppressive effects of CsA that were exhibited as increased IL-2, IL-10, CD4 and CD8 counts, implying that Phela stimulates the cell mediate immunity (CMI). Cyclosporine 63-66 Cd4 molecule Rattus norvegicus 181-184 28473245-19 2017 Co-administration of Phela 15mg/kg/day orally for 21 days with CsA led to stoppage and reversal of the immunosppressive effects of CsA that were exhibited as increased IL-2, IL-10, CD4 and CD8 counts, implying that Phela stimulates the cell mediate immunity (CMI). Cyclosporine 131-134 Cd4 molecule Rattus norvegicus 181-184 22788126-6 2012 Compared with the SIN and CsA groups, levels of CD4(+)CD25(+)FoxP3(+) lymphocytes in the control group were decreased (p < 0.05) and were increased in the cotreated group (p < 0.05). Cyclosporine 26-29 Cd4 molecule Rattus norvegicus 48-51 23724161-10 2013 CONCLUSIONS: Alloantigen induced lymphocytes to release IL-2R and P59 and stimulated the induction of the CD4 gene" transcription for 6 h. Cyclosporin A stimulated the release of IL-2R for 2 h. These results provide an in vitro basis for describing the time phases of rejection inhibited by cyclosporin A. Cyclosporine 139-152 Cd4 molecule Rattus norvegicus 106-109 23724161-10 2013 CONCLUSIONS: Alloantigen induced lymphocytes to release IL-2R and P59 and stimulated the induction of the CD4 gene" transcription for 6 h. Cyclosporin A stimulated the release of IL-2R for 2 h. These results provide an in vitro basis for describing the time phases of rejection inhibited by cyclosporin A. Cyclosporine 291-304 Cd4 molecule Rattus norvegicus 106-109 24968842-6 2014 RESULTS: In OA+CsA group, renal allograft survival was markedly prolonged and CD4(+) and CD8(+) T cell infiltration in the graft significantly decreased as compared to other groups. Cyclosporine 15-18 Cd4 molecule Rattus norvegicus 78-81 23851154-9 2013 (5) Cyclosporine A did not effectively reduce the rapid infiltration of CD4(+) or CD8(+) infiltration in 3d, but significantly reduced the degree of CD4(+) T cell infiltration in cardiac tissues between 3 and 7d. Cyclosporine 4-18 Cd4 molecule Rattus norvegicus 149-152 21692632-1 2012 BACKGROUND: The aim of this study is to evaluate CD4(+), CD8(+), and CD45RO(+) T cells, and vascular endothelial growth factor (VEGF) expression in cyclosporin A (CsA)-induced rat overgrown gingival tissue during an 8-week period. Cyclosporine 148-161 Cd4 molecule Rattus norvegicus 49-52 21692632-7 2012 RESULTS: CD4(+), CD8(+), and CD45RO(+) T cells, and VEGF expression were more prevalent in the CsA-treated group than in the control group (P <0.05). Cyclosporine 95-98 Cd4 molecule Rattus norvegicus 9-12 21692632-9 2012 CONCLUSION: Based on our findings, we conclude that VEGF, a major regulator of angiogenesis, and CD4(+), CD8(+), and CD45RO(+) memory T cells play a key role in CsA-induced gingival overgrowth. Cyclosporine 161-164 Cd4 molecule Rattus norvegicus 97-100 19100473-10 2008 RESULTS: Protosappanin A or cyclosporine significantly prolonged heart allograft survival (P < .01), alleviated myocardial pathologic damages (P < .01), decreased the CD4+/CD8+ ratio (P < .05), and inhibited perforin and granzyme B mRNA expressions in the graft (P < .05). Cyclosporine 28-40 Cd4 molecule Rattus norvegicus 173-176 20620516-6 2010 Conversely, the percentage of CD4(+)Foxp3(+) Tregs in the liver graft and blood decreased in the cyclosporine group. Cyclosporine 97-109 Cd4 molecule Rattus norvegicus 30-33 19698865-6 2009 Compared with group II, treatment with pioglitazone with low-dose cyclosporine (group IV) significantly suppressed graft infiltration of CD4/CD8 T lymphocytes and serum concentrations of interleukin 2 and interferon gamma, leading to extended graft survival up to 60 days. Cyclosporine 66-78 Cd4 molecule Rattus norvegicus 137-140 19060372-11 2008 Compared with the normal-dose CsA group, the chronic rejection lesions of the anti-ICOS-Ab combined with low-dose CsA treatment group significantly were alleviated in the long-term survival grafts, and the proportion of CD4+CD25+ regulatory T cell increased in peripheral blood. Cyclosporine 114-117 Cd4 molecule Rattus norvegicus 220-223